CJC-1295 (no DAC) vs Sermorelin

CJC-1295 (no DAC)

A short-acting GHRH analogue — the GH pulse it produces is sharp, brief, and very close to what the pituitary does on its own. Stabilised against rapid breakdown, but without the albumin-binding modification that turns it into the long-acting DAC version.

Best for

Best when you want a more stable, longer-acting GHRH (especially the DAC version) and a stronger overall signal.

Sermorelin

The oldest GHRH analogue still in widespread use — the first 29 amino acids of natural GHRH, unmodified. Pulses the pituitary in line with the body's natural sleep-onset GH window.

Best for

Best when you want the shortest, most physiologic pulse and the longer real-world safety record.

CJC-1295 (no DAC)

The pulse-amplification pharmacology is well-characterised in short human studies — Teichman and colleagues (2006) is the canonical reference and the half-life and pulse-shape data is solid. What is missing is long-term outcome data in healthy adults. The chronic safety profile is reassuring by absence of major signals across two decades of grey-market use, but absence of signal is not the same as a chronic safety trial.

Sermorelin

Sermorelin held FDA approval for paediatric GH deficiency from 1997 to 2008, when it was withdrawn from the US market for commercial — not safety or efficacy — reasons. The paediatric trial base is real and was good enough to clear regulatory review. Adult body-recomposition and anti-aging use is off-label and supported by smaller open-label work and the on-label pharmacology rather than a dedicated RCT base in healthy adults. The chronic safety record is reassuring across 25+ years of clinical and grey-market use.